Translational Genomics Research Institute

City of Hope Scientists Present Leading-Edge Research at American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Monday, April 8, 2024
Science, Biotechnology, Research, Oncology, Health, Health Technology, Genetics, Clinical Trials, Breast cancer, Survival, Immunotherapy, Health equity, Patient, Lung, City, National Cancer Institute, AGAF, Breast, MicroRNA, Pancreatic cancer, Lymphocyte, Clinical trial, Neoplasm, Therapy, Cancer, Exosome, Plasma, Colorectal cancer, Risk, Experiment, DNA, Virus, Translational Genomics Research Institute, Memory, Treatment, Cholangiocarcinoma, Pathology, Liquid biopsy, Microbiome, Recurrence, Irell & Manella, Disease, Intelligence, Molecular diagnostics, Overalls, AACR, TILS, Pancreas, Prognosis, Beckman Research Institute, Biomarker, Abdomen, Biology, Abstract, Bangladesh Technical Education Board, Data, Blood, Medical imaging

“City of Hope’s research presented at AACR’s conference this year reinforces our focus on early detection, smarter and more precise treatments, and achieving health equity.

Key Points: 
  • “City of Hope’s research presented at AACR’s conference this year reinforces our focus on early detection, smarter and more precise treatments, and achieving health equity.
  • “Cancer is complex and the breadth and diversity of research this year further underscores the talent, scientific rigor and curiosity at City of Hope,” Van den Brink added.
  • But those diagnosed when the cancer is contained to the pancreas have a 44.3% relative survival rate after five years.
  • Scientists with Translational Genomics Research Institute, part of City of Hope, also contributed to the study.

City of Hope-developed Chimeric Antigen Receptor (CAR) T Cell Therapy Shows Clinical Activity in Patients With Aggressive Brain Tumors in a Phase 1 Trial

Retrieved on: 
Thursday, March 7, 2024
Oncology, Health, Surgery, Stem Cells, Neurology, Biotechnology, Glioblastoma, Bangladesh Technical Education Board, Traffic barrier, Neoplasm, Regenerative medicine, Neurosurgery, Valadez, Multimedia, CIRM, Cerebrospinal fluid, City, Food, Cancer, GBM, Radiation, National Cancer Institute, Heritage, Human, Stroke, Safety, Organization, Patient, Spinal cord, Translational Genomics Research Institute, Brain, Survival, DSM-IV codes, Research, Environment

One of the main challenges for treating brain cancer is that medications have difficulty crossing the blood-brain barrier.

Key Points: 
  • One of the main challenges for treating brain cancer is that medications have difficulty crossing the blood-brain barrier.
  • Twenty-nine of the 58 patients with recurrent high-grade glioma brain tumors, mostly glioblastoma, achieved stable disease after treatment with CAR T cells for at least two months.
  • There were two partial responses, one complete response and a second complete response after additional CAR T cell therapy cycles were delivered under compassionate use.
  • The study team also included researchers from Translational Genomics Research Institute in Phoenix, which is part of City of Hope.

City of Hope, TGen Researchers Develop Machine-Learning Tool to Detect Cancer Earlier via Liquid Biopsy

Retrieved on: 
Wednesday, January 24, 2024
Research, Technology, Medical Devices, Genetics, Biotechnology, Pharmaceutical, Health, Science, Oncology, Artificial Intelligence, Ageing, Tomasetti, Patient, John Templeton Foundation, City, Translational Genomics Research Institute, DNA, Multimedia, DRP, Diagnosis, Whole genome sequencing, Johns Hopkins University, Nucleic acid thermodynamics, Medicine, Johns Hopkins, Cancer, Blood, Disease, Sines, Esophagus, Stage 4, Ovary, Liver, Genome, Swim Across America, National Institutes of Health, Rectum, Stomach, Breast, Lung, Clinical trial, Bangladesh Technical Education Board, Science Translational Medicine, Pancreas, Vaccine

(Photo Credit: TGen)

Key Points: 
  • (Photo Credit: TGen)
    “A huge body of evidence shows that cancer caught at later stages kills people.
  • The technology City of Hope, TGen and colleagues developed was able to identify half of the cancers in the 11 studied types.
  • Importantly, most of the cancer samples originated from people with early-stage disease, who had few or no metastatic lesions at diagnosis.
  • The prospective trial will determine the effectiveness of the biomarker panel in detecting an earlier stage of cancer when it is more treatable.

City of Hope Predicts 8 Important Cancer Trends in 2024

Retrieved on: 
Wednesday, January 17, 2024
Oncology, Health, Managed Care, General Health, Research, Science, Woman, Volunteering, Beckman Research Institute, Biology, Incidence, Prostate cancer, City, Translational Genomics Research Institute, Standard of care, Cancer, Risk, Artificial intelligence, National Cancer Institute, Acceleration, Diagnosis, Medicine, Diabetes, Deana, Stomach cancer, Geography, Irell & Manella, DNA, Policy, Bacteria, Drug development, Virus, Bone marrow, Transport, Organization, Colorectal cancer, Education, Fungus, Physician, Blood, Medicare, Hematology, Immunotherapy, Quality of life, Genetic testing, Millennials, Cell, Mortality, Patient, Federal Medical Centres, Whole genome sequencing, Lung cancer, Triple-negative breast cancer, Immune system

City of Hope is leveraging its geography as a national cancer research and treatment system and its diverse patient population to study a number of cancer disparities, including triple-negative breast cancer in African American women, lung cancer in the Asian population and colorectal cancer in the Hispanic population.

Key Points: 
  • City of Hope is leveraging its geography as a national cancer research and treatment system and its diverse patient population to study a number of cancer disparities, including triple-negative breast cancer in African American women, lung cancer in the Asian population and colorectal cancer in the Hispanic population.
  • “City of Hope will soon launch a comprehensive research study validating a blood test developed by researchers at City of Hope and TGen to detect cancers early.
  • Early detection is the key to curing cancer for many,” said Annette Walker, president of City of Hope Orange County.
  • “This is a primary reason City of Hope expanded its National Cancer Institute-designated expertise to Chicago, Phoenix and Atlanta.

Bristol Myers Squibb Announces Data at ASH 2023 from Diverse Multiple Myeloma Pipeline, Underscoring Range of Tailored Treatment Approaches to Address Unique Patient Needs

Retrieved on: 
Tuesday, December 12, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Dexamethasone, ASH, CRS, Patient, Cell, Infection, Bortezomib, B-cell maturation antigen, GPRC5D, Carfilzomib, Therapy, Bristol Myers Squibb, ORR, Cancer, Diagnosis, Anemia, International Myeloma Foundation, CD3, Cytokine release syndrome, Haematopoietic system, Multiple myeloma, Immunomodulatory imide drug, Safety, Immune system, Incidence, Aes, DOR, Science, Hook effect, Public, Drug discovery, Society, Estate (law), Lenalidomide, Proteasome inhibitor, Thrombocytopenia, PFS, BMY, Daratumumab, Neutropenia, Partnership, Skin, Life, Mezi proudy, Research, NYSE, Disease, MRD, Translational Genomics Research Institute, TCE, Survival, BMS, BCMA, Biology, Pharmaceutical industry, Vaccine, Fine chemical, Cohort, RRMM

Bristol Myers Squibb (NYSE: BMY) today announced updated results from three key programs within its broad multiple myeloma research pipeline, highlighting its diverse targets and molecular approaches to address unique patient needs within the disease.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced updated results from three key programs within its broad multiple myeloma research pipeline, highlighting its diverse targets and molecular approaches to address unique patient needs within the disease.
  • These data were presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California.
  • While multiple myeloma remains a relentless disease, we continue to transform the multiple myeloma treatment paradigm by dramatically improving outcomes for every patient.
  • As a leader in cancer care, Bristol Myers Squibb is working to empower all people with cancer to have a better future.

City of Hope Appoints Alan H. Bryce, M.D., as Chief Clinical Officer at City of Hope Cancer Center Phoenix and Professor of Molecular Medicine at TGen

Retrieved on: 
Tuesday, November 7, 2023
Oncology, Health, Genetics, Clinical Trials, Research, Science, Translational Genomics Research Institute, Clinical Genitourinary Cancer, City of Hope, Therapy, Bryce, D.O, Prostate cancer, Internal medicine, Multimedia, National Cancer Institute, Hematology, City, Genomics, Division, Clinical trial, Medicine, Molecular medicine, Melanoma, Cancer, Patient, Mayo Clinic, Dietary supplement, Pharmaceutical industry, Hope, Phoenix

City of Hope, one of the largest cancer research and treatment organizations in the United States, today announced the appointment of Alan H. Bryce , M.D., as the chief clinical officer at City of Hope Cancer Center Phoenix and professor of molecular medicine at Translational Genomics Research Institute (TGen), part of City of Hope.

Key Points: 
  • City of Hope, one of the largest cancer research and treatment organizations in the United States, today announced the appointment of Alan H. Bryce , M.D., as the chief clinical officer at City of Hope Cancer Center Phoenix and professor of molecular medicine at Translational Genomics Research Institute (TGen), part of City of Hope.
  • View the full release here: https://www.businesswire.com/news/home/20231107722066/en/
    City of Hope appoints Alan H. Bryce, M.D., as chief clinical officer at City of Hope Cancer Center Phoenix and professor of molecular medicine at TGen.
  • (Photo: City of Hope)
    “We are excited to welcome Dr. Bryce to City of Hope Cancer Center Phoenix and look forward to his leadership in delivering advanced cancer care to Arizona patients,” said Kevin Tulipana, D.O., M.S., president of City of Hope Cancer Center Phoenix.
  • “I am delighted to welcome Dr. Bryce to City of Hope and TGen,” said Jeffrey M. Trent, Ph.D., TGen president and research director.

The International Myeloma Foundation is Creating an Award-Winning Tool for Nurses to Improve Myeloma Patient Outcomes in Underserved Communities

Retrieved on: 
Thursday, November 2, 2023
Translational Genomics Research Institute, African Americans, Incidence, Multiple myeloma, Health, International Myeloma Foundation, IMF, RN, Trust, City, Nursing, Health equity, Sanofi, Bone marrow, Shared, Patient, Diagnosis, MSN, Transplant, Navigation, Pharmaceutical industry

In fact, the incidence of multiple myeloma in African Americans is 2-3 times higher than other ethnicities.

Key Points: 
  • In fact, the incidence of multiple myeloma in African Americans is 2-3 times higher than other ethnicities.
  • “The International Myeloma Foundation is addressing unmet needs and expanding our reach to underserved populations with our Innovative Shared Decision-Making and Navigation tool for nurses,” said IMF President and CEO Yelak Biru.
  • With this tool, nurses will be able to provide personalized care, reduce racial disparities, improve access to care, and ultimately enhance outcomes.
  • The International Myeloma Foundation’s Innovative Shared Decision-Making and Navigation tool educates nurses on the frontlines of myeloma care on how to best support African American and Hispanic American myeloma patients.

Volition Presents Breakthrough Liquid Biopsy Blood Test Method for Early-stage Cancer

Retrieved on: 
Monday, October 23, 2023
NHS foundation trust, The Royal Marsden NHS Foundation Trust, Real-time, Plasma, Genomics, NYSE, ESMO, Leukemia, Biomarker, Nucleic acid thermodynamics, Chromatin immunoprecipitation, Hereditary nonpolyposis colorectal cancer, Colorectal cancer, Chromatin, PCR, Research, Science, Neoplasm, FIT, Volition, Oncology, Blood, European Society for Medical Oncology, Liquid biopsy, Chemistry, Royal Marsden Hospital, Automation, Translational Genomics Research Institute, CTCF, DNA, Vaccine, Medical imaging, Coal, Cancer

Volition has developed a novel method for liquid biopsy involving the first reported physical isolation of a class of tumor-derived ctDNA fragments from blood.

Key Points: 
  • Volition has developed a novel method for liquid biopsy involving the first reported physical isolation of a class of tumor-derived ctDNA fragments from blood.
  • Removal of normal DNA obviates expensive and time-consuming DNA sequencing and bioinformatics allowing for rapid, cost-effective detection in a routine blood test."
  • Volition tested the new method in a first small clinical experiment and detected a range of liquid and other cancers, including at early stage I disease.
  • Volition has organized a data insights webinar on Thursday 26th October at 10.30 AM U.S. Eastern to provide more information about the new cancer detection method.

City of Hope and TGen Research Reveals What Potentially Causes a Leukemia to Become More Aggressive

Retrieved on: 
Wednesday, October 11, 2023
Research, Genetics, Health Technology, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Mining, Multimedia, HIV disease progression rates, Food, Division, Food and Drug Administration Amendments Act of 2007, Genome, RNA, CML, Identity provider (SAML), Carter, Heart, AML, Disease, Patient, City, Leukemia Research, City of Hope, Acute leukemia, Bone marrow, Gene, Ruxolitinib, Robert, Clinical trial, Myeloproliferative neoplasm, Mouse, Translational Genomics Research Institute, Pancreatic serous cystadenoma, Nature Communications, BP, SAML, Pharmaceutical industry, Vaccine, Medical imaging, Hope, Leukemia

View the full release here: https://www.businesswire.com/news/home/20231011243325/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231011243325/en/
    City of Hope's Guido Marcucci, M.D., and team conducted the research.
  • They found that adding miR-142 prevented CML transformation and some mice with BP CML were even cured of their disease.
  • Another track funds a diagnostic project at TGen using genomic sequencing to uncover strategies to pinpoint and prevent disease progression.
  • Thanks to the Carter Altman Foundation, the TGen team is viewing all 3 billion letters of a patient’s genome in two days or less.

National Institutes of Health To Locate Signature Research Program on the Phoenix Bioscience Core

Retrieved on: 
Friday, September 15, 2023
Knowledge, NIDDK, Translational Genomics Research Institute, Partnership, Obesity, University, Epidemiology, Cushman, PBC, SmithGroup, Knowledge enterprise, Innovation, Research, Genomics, CBRE, Bangladesh Technical Education Board, Marketing Executives Network Group, Entrepreneurship, GateWay Community College, Risk, Arizona State University, Engineering, School, Medical school, Growth, ASU, United, Biomedical sciences, Digestive, Health, NIH, World Health Organization, Pharmaceutical industry, Management, City, Wawatay Native Communications Society

PHOENIX, Sept. 15, 2023 /PRNewswire/ -- Wexford Science & Technology, LLC today announced that the National Institutes of Health has signed a lease at 850 PBC and will use the space to accommodate the Phoenix Epidemiology & Clinical Research Branch of the NIH's National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).  This innovative basic, translational, and clinical research center will occupy the entire 7th floor of 850 PBC, comprising approximately 35,000 square feet.

Key Points: 
  • "We are thrilled to announce the expansion of National Institutes of Health - NIDDK on the Phoenix Bioscience Core at 850 PBC," said Kyle Jardine, Market Executive at Wexford Science & Technology.
  • "NIH is a key research catalyst for our existing tenants, and reaffirms the PBC as Arizona's central hub for life science research and entrepreneurship.
  • The new lease at 850 PBC will allow all sections of NIDDK Phoenix to be co-located in the Phoenix Bioscience Core.
  • "It's an incredible win for Phoenix that more members of the NIDDK team will join our Phoenix Bioscience Core," City of Phoenix Mayor Kate Gallego said.